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In pulmonary inﬂammation, recruitment of circulating polymorphonuclear leukocytes is essential for host defense and initiates
the following speciﬁc immune response. One pathological hallmark of acute lung injury and acute respiratory distress syndrome
is the uncontrolled transmigration of neutrophils into the lung interstitium and alveolar space. Thereby, the extravasation of
leukocytes from the vascular system into the tissue is induced by chemokines that are released from the site of inﬂammation. The
most relevant chemokine receptors of neutrophils are CXC chemokine receptor (CXCR) 1 and CXCR2. CXCR2 is of particular
interest since several studies implicate a pivotal role of this receptor in development and promotion of numerous inﬂammatory
disorders. CXCR2 gets activated by ELR+ chemokines, including MIP-2, KC (rodents) and IL-8 (human). Since multiple ELR+
CXC chemokines act on both receptors—CXCR1 and CXCR2—a pharmacologic agent blocking both receptors seems to be
advantageous. So far, several CXCR1/2 antagonists have been developed and have been tested successfully in experimental studies.
A newly designed CXCR1 and CXCR2 antagonist can be orally administered and was for the ﬁrst time found eﬃcient in humans.
This review highlights the role of CXCR2 in acute lung injury and discusses its potential as a therapeutic target.
1.Introduction
Asanessentialcomponentoftheunspeciﬁcimmunedefense,
leukocytes migrate from the blood into inﬂammatory tissue.
Uncontrolled, excessive inﬁltration of leukocytes into the
tissue leads to a destruction of organ structure and is a main
characteristic of acute and chronic inﬂammatory disorders
like atherosclerosis, reperfusion injury or acute lung injury
(ALI) [1].
ALI and its more severe form acute respiratory distress
syndrome (ARDS) are still life-threatening syndromes pri-
marily seen on intensive care units with a mortality rate
of 40% in approximately 200,000 adult patients per year in
the USA [2]. There, the incidence of ALI was presented as
high as 86.2 per 100,000 person-years [2]. So far, outcome
can not be improved by pharmacologic treatments (e.g.,
inhaled NO, surfactant, glucocorticoids, antioxidants) [3].
Only ventilation with lower tidal volumes has shown some
beneﬁt [4].
In pulmonary inﬂammation, recruitment of circulat-
ing polymorphonuclear leukocytes (PMNs) is essential for
defense and reducing the bacterial burden in the alveolar
space—andinitiatesthefollowingspeciﬁcimmuneresponse.
If PMN migration into the lung is impaired, the immune
response is severely disturbed [5]. PMN migration into
the lung proceeds by several steps upon an inﬂammatory
stimulus: ﬁrst, accumulation of PMNs in the capillaries,
then transendothelial migration into the lung interstitium
and ﬁnally, transepithelial migration into the alveolar space.
Eachmigrationstepisregulateddiﬀerently[6].Uncontrolled
transmigration of PMNs into the interstitium of the lung
and alveolar space is a pathologic hallmark of ALI/ARDS
[7]. Experimental studies proved that modulation of PMN
traﬃcking improves tissue destruction and the outcome of
ALI [6, 8], whereas persisting neutrophilia is associated with
poor outcome [9].
The extravasation of leukocytes is controlled by
chemokines, which are released at the site of inﬂammation
and induce chemotaxis. Chemokines are small, soluble
peptides and interact with cells through speciﬁc chemokine
receptors. Besides chemotaxis, chemokines can activate
integrins that mediate leukocyte adherence on endothelial2 Mediators of Inﬂammation
cells. The existence of the multiplicity of chemokines and
theirspeciﬁcreceptorsenableselectivetraﬃckingofdiﬀerent
immune cells under normal and inﬂammatory conditions
[10–12]. So far, the existence of more than 40 members of
chemokines and 19 diﬀerent chemokine receptors has been
demonstrated [13], and most chemokine receptors have
multiple chemokine ligands.
Neutrophils are an essential component of the innate
immune system and are the ﬁrst group of cells that migrate
to sites of infection. CXC chemokine receptor (CXCR) 1 and
CXCR2 are the major chemokine receptors of neutrophils
[14–16]. CXCR2 is of particular interest since several studies
implicate a pivotal role of this receptor in development and
promotion of tumor progression and numerous inﬂamma-
tory disorders [17–24]. Acute and chronic inﬂammatory
conditions involving CXCR2 contain ischemia/reperfusion
injury, chronic obstructive pulmonary disease and ﬁbrosis
[25, 26]. In CXCR2−/− mice, neutrophil migration to sites
of inﬂammation is severely disturbed [27]. In experimental
approaches, CXCR2 antagonism is able to attenuate tissue
damage and disease progress; for example in radiation-
induced alveolitis, sepsis, peritonitis and arthritis [28–31].
ModulationofthefunctionofCXCR2isthereforeconsidered
as a possible therapeutic strategy in the treatment of
inﬂammatory conditions in humans [32].
2.CXCR2StructureandIts Ligands
Like most chemokine receptors, CXCR2 is a G protein-
coupled receptor assembled by seven transmembrane
domains and connected with heterotrimeric G proteins.
CXCR2 (and CXCR1) is expressed by granulocytes, espe-
cially neutrophils, but also by eosinophils, mast cells, T
lymphocytes and basophils [13, 39]. CXCR2 is also found on
endothelialcellswhereitalsocontributestochemotaxis[48].
In addition, CXCR2 is expressed in liver, kidney, and in cells
of the central nervous system.
CXCR1 and CXCR2 share 78% of their amino acid
s e q u e n c ea n dg e ta c t i v a t e db yE L R + chemokines (glu-
tamic acid-leucine-arginine containing). Generally, ELR+
chemokines have angiogenic activity [49] and therefore play
a pivotal role in the exudative and ﬁbroproliferative phases
of ARDS [50]. ELR+ chemokines are potent neutrophil
chemoattractants and activators and, when administered
exogenously, induce neutrophil mobilization from the bone
marrow into the circulation [51–54].
CXCR2 is the receptor for seven structurally related
ELR+ chemokines: CXCL1, CXCL2, CXCL3, CXCL6, and
CXCL8 (see Table 1 for details). CXCL8 and, to a lower
degree CXCL6, are agonists for CXCR1 and CXCR2; whereas
the other ELR+ chemokines selectively bind to and activate
CXCR2 [32, 55].
The murine CXCL1 and CXCL2/3, functional homo-
logues of human growth-related oncogenes (GROα,- β,a n d
-γ), and CXCL 8, have been identiﬁed as the primary
chemokine receptor system mediating neutrophil recruit-
ment in various models of acute and chronic inﬂammation
[26, 48, 56].
Table 1: CXCR2 ligands in mice and humans.
Systematic
name Receptor Mouse Human
CXCL1 CXCR2 KC GROα,M G S A
CXCL2 CXCR2 MIP-2 GROβ, MIP-2α
CXCL3 CXCR2 MIP-2 GROγ, MIP-2β
CXCL5 CXCR2 LIX ENA-78
CXCL6 CXCR1,2 CKα-3 GCP-2
CXCL7 CXCR2 n/a NAP-2
CXCL8 CXCR1,2 n/a IL-8
CXCR1, 2 binding ligands modiﬁed from ref. [33]. GRO: growth-
related oncogene; MGSA: melanoma growth stimulatory activity; KC:
keratinocyte-derived chemokine; MIP: macrophage inﬂammatory protein;
PF: platelet factor; ENA: epithelial cell-derived neutrophil-activating factor;
LIX:lipopolisaccharide-inducedCXChumanchemokine;GCP:granulocyte
chemotactic protein; CK: chemokine; NAP: neutrophil-activating protein;
IL: interleukin.
3. CXCRin Rodents
For a long time, rodents were believed to express only
a functional CXCR2 homologue, although an early study
demonstrated the presence of both CXCR subtypes in mice
by southern blot [57]. In the last years, however, increasing
evidence for existence and—more important—biological
activity of CXCR1 in mice has been demonstrated. One
group identiﬁed the homologues receptor to CXCR1 in mice
on chromosome 1 that is expressed on several cell types
like neutrophils, and in the kidney, liver, and spleen [58].
Since this receptor failed to be activated by known human
and murine CXC chemokines [58], it remains questionable
whether this receptor is functionally analog to the human
CXCR1. Another group found a possible CXCR1-gene in
mice genome that is 77% identical to rat gene and 58%
identical to human gene for CXCR1 [59]. In an LPS-induced
murine model, this potential CXCR1-gene was up-regulated
in PMNs that migrated into the lung [59], but there are
further studies on functional characteristics necessary to
conﬁrm this possible CXCR1-gene. Recent data demon-
strated expression of CXCR1 in mice with the corresponding
ligand CXCL6/GCP-2, both receptor and ligand associated
with murine collagen-induced arthritis [60]. There is still
additional research required to answer the question whether
rodents express CXCR1 and if so, how it interacts with
CXCR2.
4. CXCR2in Acute LungInjury
Blocking CXCR2 inhibits the release of neutrophils from the
bone marrow; consequently, exogenous administration of
CXCL1andCXCL2increasestherelease[1,61–64].Theemi-
gration of neutrophils from the bone marrow is disturbed in
micelackingCXCR2[62],causingasimilardiseasepatternas
thecongenitaldisordermyelokathexis,whichischaracterized
by chronic neutropenia due to defective emigration of PMNs
from the bone marrow.Mediators of Inﬂammation 3
In humans, elevated levels of multiple ELR+ CXC
chemokines were found in the bronchoalveolar lavage ﬂuid
of patients after ischemia-reperfusion injury [18]. In rats,
lung expression of CXCL1, CXCL2/3, and their receptor
CXCR2 were accompanied by lung neutrophil inﬁltration
and injury. Inhibition of CXCR2 or CXCR2 ligands led to a
marked reduction of migrated neutrophils into the lung and
graft injury [18].
In CXCR2−/− mice, PMN migration into the lung
was signiﬁcantly reduced in LPS-induced ALI [48]. This
eﬀect couldn’t only be ascribed to the lack of CXCR2
on PMNs as demonstrated in chimeric mice. Mice with
CXCR2 only on hematopoietic cells—like neutrophils—still
showed reduced PMN migration into the lung, but at a
higher amount compared to CXCR−/− mice. Mice with
CXCR2 only on non-hematopoietic cells—like endothelial
or epithelial cells—also demonstrated a defect in PMN
recruitment, but again, not as much as in CXCR−/− mice.
Therefore,CXCR2onhematopoieticandnon-hematopoietic
cells seems to play a pivotal role in PMN recruitment. In the
sameapproach,microvascularpermeabilitywasmeasuredby
Evans blue extravasation, and also required CXCR2 on non-
hematopoietic cells.
In hyperoxia-induced ALI, CXCR2−/− mice showed sig-
niﬁcantly reduced neutrophil sequestration and lung injury
and had a survival advantage compared with CXCR2+/+
mice [65]. In a model of ventilator-induced lung injury,
inhibitionofCXCR2ledtoamarkedreductioninneutrophil
sequestration and lung injury [17]. In bleomycin-induced
lung injury, treatment with a CXCR2 receptor antagonist
attenuated airway neutrophils but increased neutrophils in
lung parenchyma [26]. CXCR2-blocked animals showed
improved lung pathology and diminished collagen deposi-
tion. Cigarette smoke exposure induced acute inﬂammation
in the lungs of mice [38]. Blocking CXCR2 with SCH-N led
to a reduced number of neutrophils in the bronchoalveolar
lavage, decreased tissue neutrophils, and attenuated perivas-
cularinﬂammation. In apig model of aspiration of bacterial-
laden gastric contents, blocking the CXCR2 axis reduced
pulmonary neutrophilia and pathology, while maintaining
pulmonary bacterial clearance [41].
In one clinical study on CXCR2, 18 healthy volunteers
were exposed to a moderate dose of ozone (250ppb, 3h of
intermittent moderate exercise). Ozone induces a transient
increase of 20% in sputum neutrophils [46]. Pharmaco-
logical blocking of CXCR2 with the antagonist SCH527123
resulted in signiﬁcantly lower sputum neutrophil counts.
5. Pharmacological CXCR2 Blocking Strategies
Since multiple ELR+ CXC chemokines act on both re-
ceptors—CXCR1 and CXCR2—, a pharmacologic agent
blocking both receptors seems to be desirable [39]; even
though cell culture and transfection experiments also illus-
trated diﬀerences between the two receptors at cellular
and molecular levels [66]. In a recent review, the authors
concludedthatitisreasonabletoassumethatCXCR2directly
activates PMNs whereas CXCR1 may be able to slow down
migration by down-regulation of CXCR2 and acts more in
activating microbicidal properties [66].
Gernez et al. summarized that CXCR2 inhibitors are
likely to aﬀect all four pools of neutrophils [67]. These pools
are: (1) bone marrow reservoir; (2) circulating pool; (3)
neutrophils adherent to the endothelial layer; (4) tissue pool.
Generally, G protein blockers block only around 50% of
activity of the corresponding receptor. Our group showed
that heterozygote mice for CXCR2 still had a signiﬁcant
reduction on PMN migration in the interstitium of the
lung and alveolar space [48] and therefore blocking 50%
of the receptor is still eﬀective. Results with diﬀerent
pharmacologic agents blocking CXCR2 conﬁrm our results
as shown below.
Reparixin (formerly known as repertaxin), a non-
competitive allosteric inhibitor of CXCR1 and CXCR2 with
a 400-fold higher eﬃcacy in inhibiting CXCR1 activity than
CXCR2,hasbeendescribed[35].Reparixinleadstothemod-
ulation of PMN recruitment and therefore tissue damage in
experimental models of ischemia/reperfusion injury [35–37]
andorgantransplantation[68].Prophylacticandtherapeutic
application of Reparixin reduced PMN traﬃcking, vascular
permeability, and improved gas exchange in a murine model
of LPS-/acid-induced ALI [34]( Table 2). Currently, clinical
development is in process.
A potent dual inhibitor of CXCR1 and CXCR2, DF
2156A, has recently been investigated [39]. The pharmaco-
logic agent blocks the signal transduction leading to chemo-
taxis as a non-competitive inhibitor. In a murine model of
induced angiogenesis, DF 2156A attenuated inﬁltration of
leukocytes,TNF-α production and neovessel formation [39].
DF 2156A also decreased monocyte and PMN inﬁltration in
a model of rat liver ischaemia and reperfusion injury [39].
In vitro, the pharmacologic agent attenuated proliferation,
migration and capillary-like organization of human umbil-
ical vein endothelial cells after stimulation with human IL-8
[39]. Bertini and colleagues characterized DF 2156A as an
eﬀective inhibitor of CXCR1/2-mediated injury in acute and
chronic inﬂammation [39]( Table 3).
DF 2156A was also analyzed in a rat model of
ischemia/reperfusion induced by middle cerebral artery
occlusion and led to a decrease in PMN inﬁltration, infarct
size and signiﬁcantly improved neurological function [40].
ELR-CXC chemokine antagonist CXCL8(3–74)K11R/
G31P improved the course of LPS-induced lung inﬂamma-
tion in pigs as shown by decreased neutrophil migration
into the lung (approximately 86%) and reduced TNFα
(approximately 70%) and IL-1 (approximately 83%) levels
in the BAL [42]. CXCL8(3–74)K11R/G31P was also tested
in a pig model of pulmonary aspiration and led to reduced
pulmonary neutrophil response with signiﬁcantly reduced
pathology but still eﬃcient pulmonary bacterial clearance
[41].Additionally,thisspeciﬁcantagonistreducedradiation-
induced alveolitis, but not ﬁbrosis [28].
Sch527123, a potent CXCR1 and CXCR2 antagonist
with higher aﬃn i t yt oC X C R 2 ,w a sf o u n dt ob ee ﬀective
in LPS-induced ALI to reduce pulmonary PMN migration
and goblet cell hyperplasia in mice, rats and monkeys
[43]. The authors consider this speciﬁc antagonist as4 Mediators of Inﬂammation
Table 2: Pharmacological approaches on CXCR2 in animals.
Intervention Model Results Reference
Blocking CXCR2 by a
self-made antagonist∗
Lung transplant
ischemia-reperfusion injury in rats
(i) Marked reduction of neutrophils
into the lung
(ii) Attenuated graft injury
[18]
Blocking CXCR2 by a
self-made antagonist∗ Ventilator-induced ALI in mice (i) Reduced PMN sequestration and
ALI [17]
Reparixin LPS-/acid-induced ALI in mice
(i) Modulation of PMN traﬃcking
(ii) Reduced vascular permeability
(iii) Improved gas exchange
[34]
Reparixin Reperfusion injury in rats and
human/rodent PMNs
(i) Eﬀective inhibitor of PMN
recruitment
(ii) Attenuated reperfusion injury
[35]
Reparixin Cerebral ischemia in rats
(i) Anti-inﬂammatory and
neuroprotective eﬀects
(ii) Inhibition of PMN inﬁltration
(iii) Reduced tissue damage
[36]
Reparixin Intestinal ischemia and reperfusion
injury in rats
(i) Reduced neutrophil inﬂux
(ii) Reduced microvascular





inﬂammation and ﬁbrosis in mice
(i) Improvement of lung pathology
(ii) Reduced collagen deposition
(iii) Reduced airway PMN migration
(iv) Increased PMN in lung
parenchyma
[26]
SCH-N Cigarette smoke-induced lung
inﬂammation in mice
(i) Reduced PMNs in BAL
(ii) Reduced perivascular
inﬂammation





ischemia/reperfusion injury in rats





organization of human umbilical vein
endothelial cells
[39]
DF2156A Ischemia/reperfusion injury in rats
(i) Decrease of PMN inﬁltration
(ii) Reduced infarct size
(iii) Improved neurological function
[40]
K11R/G31P Aspiration pneumonia in pigs
(i) Attenuated neutrophil response
(ii) Reduced pathology
(iii) Still eﬃcient pulmonary bacterial
clearance
[41]
K11R/G31P LPS-induced lung inﬂammation in
pigs
(i) Decreased PMN migration into the
lung
(ii) Reduced TNFα andl IL-1 levels in
the BAL
[42]
K11R/G31P Radiation-induced lung injury in
mice (i) Reduced alveolitis but not ﬁbrosis [28]
Sch527123∗
Intranasal/intratracheal
LPS-administration in mice, and
rats, repeated bronchoscopy and
lavage in cynomolgus monkey
(i) Suppressed pulmonary
neutrophilia
(ii) Reduced goblet cell hyperplasia
[43]
Simvastatin Streptococcal-induced ALI in mice (i) Reduced inﬁltration of neutrophils
and edema in the lung [44]
∗Selective for CXCR2; the other pharmacologic agents also inhibit CXCR1.Mediators of Inﬂammation 5
Table 3: Pharmacological approaches on CXCR2 in humans.




ischemia/reperfusion injury in rats
(i) Decreased monocyte and PMN inﬁltration
(ii) Reduced TNFα
(iii) Attenuated proliferation,
migration and capillary-like organization of
human umbilical vein endothelial cells
[39]
Sch527123 Human neutrophils (i) Inhibited neutrophil chemotaxis
(ii) Inhibited myeloperoxidase release [45]
Sch527123 Ozone-induced neutrophil
recruitment in humans (i) Lower sputum neutrophil count [46]
SB-65933∗ Ozone-induced airway
inﬂammation in humans
(i) Lower neutrophil activation and
recruitment [47]
∗Selective for CXCR2, the other pharmacologic agents also inhibit CXCR1.
a possible treatment of inﬂammatory lung disorders in
which pulmonary neutrophilia and mucus hypersecretion
are the leading symptoms, for example COPD (chronic
obstructive pulmonary disease), asthma, cystic ﬁbrosis, and
ARDS. Sch527123 is also a potent, selective antagonist of
the human CXCR1 and CXCR2, as shown in in vitro
assays [45]. Sch527123 is also eﬀective when given orally.
In healthy humans, SCH527123 inhibited ozone-induced
neutrophil recruitment [46]. The authors concluded that
further evaluation in a large trial of patients with pulmonary
disorders is warranted.
A recently published study investigated the eﬀect of
simvastatin in streptococcal-induced ALI [44]. In a murine
model, simvastatin led to a decrease of PMN inﬁltration,
most likely through reduced pulmonary release of CXC
chemokines.
GSK1325756, a potent, competitive CXCR2 receptor
antagonist developed for the treatment of chronic obstruc-
tive pulmonary disease (COPD) is currently investigated
with the question how the pharmacokinetic is aﬀected by
age, gender and food (high fat meal) (http://www.clinical-
trials.gov/).Currently,thereisnodataavailableontheeﬀects
of this drug in ALI.
SB-656933, a selective CXCR2 antagonist, was inves-
tigated in ozone-induced airway inﬂammation in healthy
humans [47]. SB-656933 revealed dose-dependent eﬀects
on neutrophil activation and recruitment within a well-
tolerated dose range. The authors concluded that this agent
may be eﬀective in neutrophil-predominant diseases. Cur-
rently, one clinical study on the safety, tolerability, steady
state pharmacokinetics and pharmacodynamics of SB-
656933 in repeated doses is carried out (http://www.clinical-
trials.gov/).
6.Blocking CXCR2—Think Twice
In certain inﬂammatory diseases with special pathogens, a
functionalCXCR2isrequiredforneutrophilrecruitmentand
pathogenelimination.CXCR2knockoutmiceorantagonism
of the receptor led to massive bacterial/fungal outgrowth
in Pseudomonas aeruginosa [69], Nocardia asteroides [70],
Aspergillus fumigatus [71], and Streptococcus pneumonia
[72]—infections.
Therefore, further studies on blocking CXCR2 under
diﬀerent disease conditions are needed to understand its
mode of action and to ﬁnd out interactions with other
r e c e p t o r s .T h i sa t t e m p ti sq u i t ed i ﬃcult since typically,
upon activation of ligands, chemokine receptors are quickly
desensitized and internalized and therefore have only around
30 seconds for signal transmitting [13].
However, there is one recently discovered example of
formerly unknown interactions: receptor oligomerization
can lead to a novel signal cascade besides the normal signal
pattern. One group found a hetero-oligomerization of the
human DOP opioid and CXCR2 receptors [73]. Thereby, a
CXCR2 antagonist increased the function of DOP receptor
agonists, but only if CXCR2 was expressed. The study
suggests that a CXCR2 receptor antagonist is capable to
enhance a DOP receptor agonist by acting as an allosteric
regulator of a receptor which is a heterodimer partner for the
CXCR2 receptor [73].
7. Conclusion
In summery, CXCR2 plays a pivotal role in ALI with
regard to neutrophil recruitment from the bone marrow, the
circulating pool, neutrophils adherent to the endothelium,
and the tissue pool. Pharmacologic blocking strategies
appear promising in many disease conditions, and in several
experimental studies blocking CXCR2 has been shown to
attenuatetissuedamageunddiseaseprogress.Pharmacologic
blocking agents are even orally available and oﬀer promising
results in humans, but further studies with a larger cohort
are needed. There are further investigations on this receptor
necessary about its functions and interactions in relation to
other receptors.
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